Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumors.
Cytokine release syndrome
Dose escalation study
Human leukocyte antigen-G
JNJ-78306358
Phase 1
Solid tumors
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
22
03
2024
accepted:
22
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors. Adult patients with metastatic/unresectable solid tumors with high prevalence of HLA-G expression were enrolled. Dose escalation was initiated with once-weekly subcutaneous administration with step-up dosing to mitigate cytokine release syndrome (CRS). Overall, 39 heavily pretreated patients (colorectal cancer: n = 23, ovarian cancer: n = 10, and renal cell carcinoma: n = 6) were dosed in 7 cohorts. Most patients (94.9%) experienced ≥ 1 treatment-emergent adverse events (TEAEs); 87.2% had ≥ 1 related TEAEs. About half of the patients (48.7%) experienced CRS, which were grade 1/2. Nine patients (23.1%) received tocilizumab for CRS. No grade 3 CRS was observed. Dose-limiting toxicities (DLTs) of increased transaminases, pneumonitis and recurrent CRS requiring a dose reduction were reported in 4 patients, coinciding with CRS. No treatment-related deaths reported. No objective responses were noted, but 2 patients had stable disease > 40 weeks. JNJ-78306358 stimulated peripheral T cell activation and cytokine release. Anti-drug antibodies were observed in 45% of evaluable patients with impact on exposure. Approximately half of archival tumor samples (48%) had expression of HLA-G by immunohistochemistry. JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).
Sections du résumé
BACKGROUND
BACKGROUND
JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors.
METHODS
METHODS
Adult patients with metastatic/unresectable solid tumors with high prevalence of HLA-G expression were enrolled. Dose escalation was initiated with once-weekly subcutaneous administration with step-up dosing to mitigate cytokine release syndrome (CRS).
RESULTS
RESULTS
Overall, 39 heavily pretreated patients (colorectal cancer: n = 23, ovarian cancer: n = 10, and renal cell carcinoma: n = 6) were dosed in 7 cohorts. Most patients (94.9%) experienced ≥ 1 treatment-emergent adverse events (TEAEs); 87.2% had ≥ 1 related TEAEs. About half of the patients (48.7%) experienced CRS, which were grade 1/2. Nine patients (23.1%) received tocilizumab for CRS. No grade 3 CRS was observed. Dose-limiting toxicities (DLTs) of increased transaminases, pneumonitis and recurrent CRS requiring a dose reduction were reported in 4 patients, coinciding with CRS. No treatment-related deaths reported. No objective responses were noted, but 2 patients had stable disease > 40 weeks. JNJ-78306358 stimulated peripheral T cell activation and cytokine release. Anti-drug antibodies were observed in 45% of evaluable patients with impact on exposure. Approximately half of archival tumor samples (48%) had expression of HLA-G by immunohistochemistry.
CONCLUSION
CONCLUSIONS
JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).
Identifiants
pubmed: 39105878
doi: 10.1007/s00262-024-03790-7
pii: 10.1007/s00262-024-03790-7
doi:
Substances chimiques
Antibodies, Bispecific
0
HLA-G Antigens
0
CD3 Complex
0
Banques de données
ClinicalTrials.gov
['NCT04991740']
Types de publication
Journal Article
Clinical Trial, Phase I
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
205Informations de copyright
© 2024. The Author(s).
Références
Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L (2023) Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther 8:9. https://doi.org/10.1038/s41392-022-01270-x
doi: 10.1038/s41392-022-01270-x
pubmed: 36604431
pmcid: 9816309
Wei J, Yang Y, Wang G, Liu M (2022) Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol 13:1035276. https://doi.org/10.3389/fimmu.2022.1035276
doi: 10.3389/fimmu.2022.1035276
pubmed: 36389699
pmcid: 9650279
Rader C (2020) Bispecific antibodies in cancer immunotherapy. Curr Opin Biotechnol 65:9–16. https://doi.org/10.1016/j.copbio.2019.11.020
doi: 10.1016/j.copbio.2019.11.020
pubmed: 31841859
Sun Y, Yu X, Wang X et al (2023) Bispecific antibodies in cancer therapy: target selection and regulatory requirements. Acta Pharm Sin B 13:3583–3597. https://doi.org/10.1016/j.apsb.2023.05.023
doi: 10.1016/j.apsb.2023.05.023
pubmed: 37719370
pmcid: 10501874
US Food and Drug Administration (2023) Bispecific antibodies: an area of research and clinical applications. Retrieved from: https://www.fda.gov/drugs/news-events-human-drugs/bispecific-antibodies-area-research-and-clinical-applications . Accessed Nov 9, 2023
Zhuang B, Shang J, Yao Y (2021) HLA-G: an important mediator of maternal-fetal immune-tolerance. Front Immunol 12:744324. https://doi.org/10.3389/fimmu.2021.744324
doi: 10.3389/fimmu.2021.744324
pubmed: 34777357
pmcid: 8586502
Lin A, Yan WH (2018) Heterogeneity of HLA-G expression in cancers: facing the challenges. Front Immunol 9:2164. https://doi.org/10.3389/fimmu.2018.02164
doi: 10.3389/fimmu.2018.02164
pubmed: 30319626
pmcid: 6170620
Lin A, Yan WH, Xu HH, Gan MF, Cai JF, Zhu M, Zhou MY (2007) HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol Off J Eur Soc Med Oncol 18:1804–1809. https://doi.org/10.1093/annonc/mdm356
doi: 10.1093/annonc/mdm356
Lin A, Yan WH (2015) Human leukocyte antigen-G (HLA-G) expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med 21:782–791. https://doi.org/10.2119/molmed.2015.00083
doi: 10.2119/molmed.2015.00083
pubmed: 26322846
pmcid: 4749493
Lin A, Yan WH (2019) Intercellular transfer of HLA-G: its potential in cancer immunology. Clin Transl Immunology 8:e1077. https://doi.org/10.1002/cti2.1077
doi: 10.1002/cti2.1077
pubmed: 31489189
pmcid: 6716982
Lin A, Yan WH (2021) HLA-G/ILTs targeted solid cancer immunotherapy: opportunities and challenges. Front Immunol 12:698677. https://doi.org/10.3389/fimmu.2021.698677
doi: 10.3389/fimmu.2021.698677
pubmed: 34276691
pmcid: 8278316
Morandi F, Airoldi I (2022) HLA-G and other immune checkpoint molecules as targets for novel combined immunotherapies. Int J Mol Sci 23:2925
doi: 10.3390/ijms23062925
pubmed: 35328349
pmcid: 8948858
Obermajer N, Zwolak A, Van De Ven K et al (2022) Abstract ND07: JNJ-78306358: a first-in-class bispecific T cell redirecting HLA-G antibody. Cancer Res 82:ND07–ND07. https://doi.org/10.1158/1538-7445.Am2022-nd07
doi: 10.1158/1538-7445.Am2022-nd07
Fucà G, Spagnoletti A, Ambrosini M, de Braud F, Di Nicola M (2021) Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. ESMO Open 6:100046. https://doi.org/10.1016/j.esmoop.2020.100046
doi: 10.1016/j.esmoop.2020.100046
pubmed: 33508733
pmcid: 7841318
Haense N, Atmaca A, Pauligk C et al (2016) A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors. BMC Cancer 16:420. https://doi.org/10.1186/s12885-016-2449-0
doi: 10.1186/s12885-016-2449-0
pubmed: 27387446
pmcid: 4937525
Hummel HD, Kufer P, Grüllich C et al (2021) Pasotuxizumab, a BiTE(®) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13:125–141. https://doi.org/10.2217/imt-2020-0256
doi: 10.2217/imt-2020-0256
pubmed: 33172323
Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transp J Am Soc Blood Marrow Transp 25:625–638. https://doi.org/10.1016/j.bbmt.2018.12.758
doi: 10.1016/j.bbmt.2018.12.758
Shah D, Soper B, Shopland L (2023) Cytokine release syndrome and cancer immunotherapies-historical challenges and promising futures. Front Immunol 14:1190379. https://doi.org/10.3389/fimmu.2023.1190379
doi: 10.3389/fimmu.2023.1190379
pubmed: 37304291
pmcid: 10248525
Zhou S, Liu M, Ren F, Meng X, Yu J (2021) The landscape of bispecific T cell engager in cancer treatment. Biomark Res 9:38. https://doi.org/10.1186/s40364-021-00294-9
doi: 10.1186/s40364-021-00294-9
pubmed: 34039409
pmcid: 8157659
Simão DC, Zarrabi KK, Mendes JL, Luz R, Garcia JA, Kelly WK, Barata PC (2023) Bispecific T-cell engagers therapies in solid tumors: focusing on prostate cancer. Cancers 15:1412
doi: 10.3390/cancers15051412
pubmed: 36900202
pmcid: 10001031
Contini P, Murdaca G, Puppo F, Negrini S (2020) HLA-G expressing immune cells in immune mediated diseases. Front Immunol 11:1613. https://doi.org/10.3389/fimmu.2020.01613
doi: 10.3389/fimmu.2020.01613
pubmed: 32983083
pmcid: 7484697
Moroso V, van Cranenbroek B, Mancham S et al (2015) Prominent HLA-G expression in liver disease but not after liver transplantation. Transplantation 99:2514–2522. https://doi.org/10.1097/TP.0000000000000761
doi: 10.1097/TP.0000000000000761
pubmed: 25961490
Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H (2007) HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood 110:568–577. https://doi.org/10.1182/blood-2006-11-057125
doi: 10.1182/blood-2006-11-057125
pubmed: 17371944
de Oliveira Crispim JC, Silva TGA, Souto FJD et al (2012) Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infection. Hum Immunol 73:258–262. https://doi.org/10.1016/j.humimm.2011.12.004
doi: 10.1016/j.humimm.2011.12.004
pubmed: 22178697
Hazini A, Fisher K, Seymour L (2021) Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002899
doi: 10.1136/jitc-2021-002899
pubmed: 34353849
pmcid: 8344275
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS (2018) Cytokine release syndrome. J Immunother Cancer 6:56. https://doi.org/10.1186/s40425-018-0343-9
doi: 10.1186/s40425-018-0343-9
pubmed: 29907163
pmcid: 6003181
Bröske AE, Korfi K, Belousov A et al (2022) Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. Blood Adv 6:1025–1037. https://doi.org/10.1182/bloodadvances.2021005954
doi: 10.1182/bloodadvances.2021005954
pubmed: 34941996
pmcid: 8945294
Middleton MR, McAlpine C, Woodcock VK et al (2020) Tebentafusp, a TCR/Anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 26:5869–5878. https://doi.org/10.1158/1078-0432.Ccr-20-1247
doi: 10.1158/1078-0432.Ccr-20-1247
pubmed: 32816891
pmcid: 9210997
Himmels P, Nguyen TTT, Mitzner MC et al (2023) T cell-dependent bispecific antibodies alter organ-specific endothelial cell–T cell interaction. EMBO Rep 24:e55532. https://doi.org/10.15252/embr.202255532
doi: 10.15252/embr.202255532
pubmed: 36621885
pmcid: 9986820
Ball K, Dovedi SJ, Vajjah P, Phipps A (2023) Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs 15:2181016. https://doi.org/10.1080/19420862.2023.2181016
doi: 10.1080/19420862.2023.2181016
pubmed: 36823042
pmcid: 9980545
Matasar MJ, Cheah CY, Yoon DH et al (2020) Subcutaneous mosunetuzumab in relapsed or refractory B-Cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood 136:45–46. https://doi.org/10.1182/blood-2020-135818
doi: 10.1182/blood-2020-135818
Lesokhin AM, Levy MY, Dalovisio AP et al (2020) Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood 136:8–9. https://doi.org/10.1182/blood-2020-133355
doi: 10.1182/blood-2020-133355
Lim EA, Schweizer MT, Chi KN et al (2023) Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 21:366–375. https://doi.org/10.1016/j.clgc.2023.02.010
doi: 10.1016/j.clgc.2023.02.010
pubmed: 36948922
Luke JJ, Barlesi F, Chung K et al (2021) Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J Immunother Cancer. https://doi.org/10.1136/jitc-2020-002015
doi: 10.1136/jitc-2020-002015
pubmed: 34389618
pmcid: 8365809
Pistoia V, Morandi F, Wang X, Ferrone S (2007) Soluble HLA-G: are they clinically relevant? Semin Cancer Biol 17:469–479. https://doi.org/10.1016/j.semcancer.2007.07.004
doi: 10.1016/j.semcancer.2007.07.004
pubmed: 17825579
pmcid: 2200630
Katharine R, Nataša O, Adam Z, Stephen J, Brian Geist GP. Mechanism-based pharmacokinetic/pharmacodynamic modeling of JNJ-78306358, a CD3 redirector targeting HLA-G in solid tumors. In: American conference on pharmacometrics (ACoP14), National Harbor, Maryland, USA
Hodges D, Kochel C, Totagrande M et al (2020) 698 targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody. J Immunother Cancer 8:A419–A420. https://doi.org/10.1136/jitc-2020-SITC2020.0698
doi: 10.1136/jitc-2020-SITC2020.0698
Naing A, Wang JS, Sharma MR et al (2022) 174P first-in-human study of NGM707, an ILT2/ILT4 dual antagonist antibody in advanced or metastatic solid tumors: preliminary monotherapy dose escalation data. Immuno-Oncol Technol. https://doi.org/10.1016/j.iotech.2022.100286
doi: 10.1016/j.iotech.2022.100286
Siu LL, Wang D, Hilton J et al (2022) First-in-class anti-immunoglobulin–like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors. Clin Cancer Res 28:57–70. https://doi.org/10.1158/1078-0432.Ccr-21-2160
doi: 10.1158/1078-0432.Ccr-21-2160
pubmed: 34598945
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer. https://www.globenewswire.com/news-release/2023/03/16/2629209/0/en/Jounce-Therapeutics-Announces-Results-from-Pre-Planned-Data-Review-of-INNATE-Phase-2-Trial-of-JTX-8064-and-Pimivalimab-Demonstrating-Deep-and-Durable-Responses-in-Platinum-Resistan.html
Banerjee R, Marsal J, Huang CY et al (2021) Early time-to-tocilizumab after B cell maturation antigen-directed chimeric antigen receptor T cell therapy in myeloma. Transpl Cell Ther 27:477e1-e7. https://doi.org/10.1016/j.jtct.2021.03.004
doi: 10.1016/j.jtct.2021.03.004